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ABSTRACT  
 
MAGEA1, a member of type I melanoma antigens genes (MAGE), is only expressed in male 
germ cells and in cancer cells of several histological types. Some evidences support the 
hypothesis that MAGEA genes are expressed to provide a survival advantage to tumor cells. 
First, type I MAGE genes are able to inhibit the activity and decrease the level of the tumor 
suppressor p53. Secondly, MAGEA gene expression is associated with tumor invasiveness, 
lymph node metastasis, poor prognosis and advanced clinical stage. Moreover, MAGEA1 
expression is also associated with increased chemoresistance. The purpose of my work was to 
study the involvement of MAGEA1 in tumor development using in vivo and in vitro models.  
 
The in vivo model involves the generation of transgenic mice expressing MAGEA1 
ectopically in melanocytes. Expression of MAGEA1 transgene in mouse tissues was analyzed 
by quantitative RT-PCR. Preliminary results showed different levels of MAGEA1 transcripts 
in the skin of each mouse lineage, but not in the other examined tissues (testis, heart, liver and 
brain).  
 
The second goal of my project was to study the oncogenic functions of MAGEA1 in vitro. 
Using cell survival assays, a mechanism of chemoresistance conferred by MAGEA1 was 
detected in two different cell models (MCF-10A and MCF-7 cells) after treatment with 
etoposide, 5-fluorouracil and docetaxel. Complementary survival tests on Hep3B cells, a p53-
deficient cell model, did not reveal chemoresistance in presence of MAGEA1 except after 
docetaxel treatment, a drug reported to work independently of p53 pathway. Forced 
expression of MAGEA1 by transduction induced an overexpression of ABC transporters 
mRNA in MCF-10A cells but not in Hep3B cells. As these transporters are mediators of 
chemoresistance, the induction of ABC transporters by MAGEA1 could represent a new 
mechanism of the chemoresistance induced by MAGEA1. In parallel, cell migration assays 
indicated that MAGEA1 also conferred a migratory advantage to MCF-10A cells, but not to 
Hep3B.  
 
INVOLVEMENT OF MAGEA1 GENE IN TUMORIGENESIS:  
IN VIVO AND IN VITRO MODELS  
 
WILLEMS Estelle 
 
 
 
2 
 
ACKNOWLEDGEMENTS   
 
 
 
Thanks to the professor Olivier De Backer for his welcome in the lab and for his 
sensible advices during my work 
 
 
 
 
 
Thanks to Elise for her useful and precious assistance during all the period of my work 
 
 
 
 
 
Thanks to Olivia, Domi, Coco, François, Christiane, Emilie, J-M, Gégé and all the lab 
of Genetics for their valuable help and their daily support 
 
 
 
 
 
Thanks to the professors N. Caron, J-P Gillet, J-Y Matroule as well as V. Bourguignon 
for the time and attention dedicated for the reading of my report 
 
 
 
 
 
Thanks to my father for his precious advices and support. Thanks to my mother and to 
Marie, Thibault, Adeline, Justine, Caro, etc for their precious encouragement and their moral 
support during this period 
 
 
 
 
 
 
 
 
Thanks  
 
 
 
3 
 
SUMMARY 
INTRODUCTION 5 
I. CANCER TESTIS ANTIGENS 5 
II. MAGE GENE FAMILY 5 
III. TYPE I MAGE GENES 7 
1) EXPRESSION PATTERN OF TYPE I MAGE GENES 7 
Regulation of transcription 8 
Expression in mice 9 
Expression in male germ cells 9 
2) ROLES OF TYPE I  MAGE GENES 10 
Influence of the type I MAGE on the tumor suppressor p53 10 
Induction of the hypoxic response 13 
Inhibition of caspases 13 
Pro-apoptotic activity 13 
V. INVOLVEMENT IN TUMORIGENESIS 14 
1) CHEMORESISTANCE 14 
2) CELL MIGRATION AND INVASION 15 
3) IMMUNOTHERAPY 15 
VI. METHODS OF TRANSGENESIS 16 
VIII.  OBJECTIVES AND WORKPLAN 17 
MATERIALS AND METHODS 19 
I. PINSULATOR-TYRP-MAGEA1  PLASMID DESIGN 19 
II. MICE GENOTYPING 19 
III. CELL CULTURE 20 
IV. CALCIUM-DEPENDENT TRANSFECTION AND CELL TRANSDUCTION 21 
V. WESTERN-BLOT 21 
VI. REVERSE TRANSCRIPTION AND QUANTITATIVE PCR 22 
VII. MTT TEST 23 
VIII. SCRATCH TEST 23 
 
4 
 
RESULTS: 24 
IN VIVO MODELS 24 
I. ADDITIVE TRANSGENESIS: THE TYRP-MAGEA1 TRANSGENIC MICE 24 
1) THE TYRP-MAGEA1 TRANSGENE 24 
2) GENERATION OF TYRP-MAGEA1 TRANSGENIC MICE 26 
3) CHARACTERISATION OF TYRP-MAGEA1 TRANSGENIC MICE 27 
II. TARGETED TRANSGENESIS: THE ROSA26-MAGEA1 TRANSGENIC MICE 29 
IN VITRO MODELS 31 
I. MAGEA1 AND CELL CHEMORESISTANCE 31 
1) CHEMORESISTANCE IN A P53 WILD-TYPE CELL MODEL 31 
2) CHEMORESISTANCE IN A P53 DEFICIENT CELL MODEL 35 
II. MAGEA1 AND ABC TRANSPORTERS EXPRESSION 38 
1) ABC TRANSPORTERS EXPRESSION IN A P53 WILD-TYPE CELL MODEL 38 
2) ABC TRANSPORTERS EXPRESSION IN A P53-DEFICIENT CELL MODEL 39 
III. MAGEA1 AND CELL MIGRATION 40 
1) EFFECT OF MAGEEA1 ON MIGRATION IN A P53 WILD-TYPE CELL MODEL 40 
2) EFFECT OF MAGEA1 ON MIGRATION IN A P53-DEFICIENT CELL MODEL 40 
IN VIVO MODELS 44 
IN VITRO MODELS 47 
 
 
 
 
 
 
 
 
5 
 
INTRODUCTION 
 
I. CANCER TESTIS ANTIGENS 
 
 Since the 1980s, tumor specific antigens have raised the interest of many research 
teams in the field of anticancer immunotherapy (Fearon et al, 1988; Van Pel et al, 1992). 
Most of the clinical trials of tumor vaccination focus on melanoma, a cancer type 
characterized by numerous surface antigens (Chin et al, 2006).  
 
Cancer testis antigens (CTA), a family of tumor specific antigens, are silenced in 
normal tissues except in cells of male germ-line. Interestingly, an ectopic expression of CTA 
has been identified in several histological tumor types, making them an attractive target for 
anticancer immunotherapy (Doyle et al, 2010; Gjerstorff et al., 2008). CTA, derived from 
endogenous proteins, are presented on cell surface by molecules of the major 
histocompatibility complex (MHC) and recognized by cytotoxic T cells (van der Bruggen et 
al, 1991). The role of CTA is not yet defined, but some evidences support their implication in 
proliferation, differentiation and survival of germinal cells (Gjerstorff et al, 2008).  
 
In 1991, van der Bruggen et al identified the gene coding for a CTA named MZ2-E 
(van der Bruggen et al, 1991). To this end, a cosmid library was prepared with the DNA of a 
melanoma cell line expressing MZ2-E and these cosmids were transfected in melanoma cells 
that do not express MZ2-E. Cell sensitivity to lymphocytes directed against MZ2 was tested, 
leading to the identification of MZ2-positive cells. This work allowed the identification of the 
gene which directs the expression of MZ2-E, now called MAGEA1 and presented by HLA-
A1 molecules at the cell surface (Traversari et al, 1992). 
 
 
 
II. MAGE GENE FAMILY  
 
 The melanoma antigen genes (MAGE) are divided in two main families: type I and 
type II MAGE genes, according to their expression pattern. Within these two families, MAGE 
genes are classified in different groups (MAGEA, MAGEB, etc) depending on their 
chromosomal localization and sequences similarity (De Plaen et al. 1994; Chomez et al., 
2001).  
 
All MAGE proteins contain a well conserved domain of 165 to 170 amino acids, 
named Mage Homology Domain (MHD) (see Figure 1 and 2) (Chomez et al., 2001). The 
amino acid sequence of this MHD is characterized by a global conservation rate of 46%. This 
conservation rate increases within MAGE subfamilies, with 75% between MAGED genes and 
70% in the MAGEA family. This high conservation indicates an important role of the MHD 
that is not fully understood. 
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Figure 1: Chromosomal localization of human MAGE genes subfamilies 
 
 
 
Figure 2: Illustration of the structural organization of MAGE proteins  
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  Type I MAGE genes, present in clusters on the X chromosome, encode members of 
the CTA family that are exclusively expressed in male germ cells as well as at the surface of 
tumoral cells. Actually, some of the type I MAGE proteins are degraded through the 
proteasomal pathway in peptides. The MAGE peptides are then carried into the endoplasmic 
reticulum, associated with molecules of the class I HLA and presented to the cell membrane. 
Nowadays, more than thirty-five type I MAGE genes are described. Type I MAGE genes are 
divided in three sub-groups: 12 MAGEA genes are located in Xq28, 18 MAGEB in Xp21 and 
7 MAGEC in Xq26-27 (Figure 1). At a structural level, type I MAGE genes are characterized 
by a large 3’-exon coding for the entire protein. The amino acid structure of type I MAGE 
proteins is limited to the MHD, surrounded by short C- and N-terminal sequences (Chomez et 
al, 2001).  
 
Our work focuses on MAGEA1 gene that is expressed in 40%  of melanomas, 17% of 
mammary carcinomas, 35% of non-small cell lung carcinomas and 21% of bladder 
carcinomas (De Smet et al., 1995). MAGEA1 gene, spreading over 4,5 kilobases, contains 
three exons the first of which codes the entire protein. 
 
The type II MAGE genes, present on the X chromosome and on autosomes, exhibit 
three main structural differences compared to type I MAGE genes. First, their coding 
sequence is spread on several exons. Then, type II MAGE proteins are structurally more 
complex, with longer N- and C-terminal extremities than most type I MAGE proteins. Finally, 
some type II MAGE genes have a duplicated MHD (namely, MAGEE1 and MAGEE2) 
(Barker & Salehi 2002; Doyle et al. 2010; Jung et al., 2005). Type II MAGE genes are 
expressed in various somatic cells at different developmental stages. Their role is not exactly 
determined, but some findings suggest an involvement in apoptosis, cell differentiation and, 
indirectly, in behaviour control (Dombret et al. 2012; Mouri et al. 2012; Wang et al. 2010). 
These last years, type II MAGE genes were being studied thoroughly in our lab. In 2010, 
Nguyen discovered that Maged1 mouse gene is required for proper skeletal myoblast 
differentiation and muscle healing (Nguyen et al., 2010). Two years later, Dombret et al 
suggested that MAGE-D1 loss results in oxytocin production problems, deficits of social 
interactions, impaired sexual behavior and obesity (Dombret et al., 2012). A plausible 
hypothesis is that MAGE-D1 could play a role in autism or cause a neuro-developmental 
condition that is reminiscent of the Prader-Willi syndrome. Other type II MAGE genes are 
less characterized and further studies are needed to define their precise function.  
 
 
III. TYPE I MAGE GENES  
 
1) Expression pattern of type I MAGE genes    
 
  Type I MAGE genes are exclusively expressed in male germ cells and in cancer cells 
of several histological types such as brain, breast, liver, lung, ovary, prostate, skin, testis, 
thyroid and pancreatic cancers (Caballero et al., 2010; Chomez et al., 1995; Doyle et al., 
2010; Takahashi et al., 1995). The specific expression of MAGE proteins in tumoral tissues 
makes them an attractive target for immunotherapy (Sang et al., 2010).  
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Regulation of transcription  
 
  Expression pattern of type I MAGE genes have intrigued the interest of several teams, 
such as that of De Smet et al who have studied the regulation of transcription (De Smet et al., 
1995). This team identified a family of transcription factors required for promoter activation, 
named Ets that are ubiquitously expressed in healthy somatic cells. The Ets binding domain 
present in the promoter of MAGEA1 is adjacent to a CpG island and can be silenced by 
methylation. Moreover, treatment with 5’aza-2’-deoxycytidine, a demethylating agent, was 
able to induce type I MAGE expression both in cancer and healthy cells (Weber et al., 1994; 
De Smet et al, 1996; Jung et al., 2004). These data are consistent with the correlation between 
the level of DNA methylation and the expression of MAGEA genes. Indeed, the percentage of 
genome methylation decreases to 29% in cancer cells positive for MAGEA1, for a level of 
52% in cells not expressing MAGEA1 (De Smet et al, 1996; De Smet et al, 1999).  
 
Actually, even if methylation is the predominant epigenetic regulation of MAGE 
genes expression, chromatin modulation influenced by histone acetyltransferases and 
deacetylases, also controls the expression of type I MAGE gene (Wischnewski et al., 2006). 
These observations and others led to the conclusion that, in healthy cells, the expression of 
type I MAGE genes is prevented by DNA and histones methylation. It has been shown that 
other type I MAGE genes are regulated in the same way (De Smet et al., 1996; De Smet et al, 
1999).  
 
Afterwards, De Smet et al focused specifically on the epigenetic regulation of the 
MAGEA1 gene. They discovered that the hypo-methylation of the MAGEA1 promoter in 
cancerous cells relies on a transient process of de-methylation, followed by an inhibition of 
re-methylation by specific transcription factors (De Smet et al, 2004). This finding could 
explain why specific DNA sequences, such as MAGE promoters, stay un-methylated despite 
the activity of DNA methyltransferase (DNMT). Moreover, this hypothesis also gives an 
explanation for the characteristic pattern of methylation in tumor cells, corresponding to the 
coexistence of hypo-methylated and hyper-methylated regions (Ehrlich et al, 2002). The team 
tested his hypothesis by determining that the induction of a transient de-methylation phase, 
induced by inhibition of the DNMT1, was sufficient to convert a methylated MAGEA1 
transgene into an un-methylated and active one (Loriot et al, 2006).  
  
It is prominent to note that some CTA genes, including MAGE genes, are also 
expressed in trophoblast during embryogenesis. However, the developmental stage at which 
MAGE genes acquire DNA methylation marks was not yet determined. But in 2012, Loriot 
and his team demonstrated that the transcription of CTA genes increases up to the morula 
stage and then diminish drastically in blastocyst (Loriot et al, 2012). This observation 
suggests that CTA are programmed for repression in the blastocyst probably by de novo DNA 
methylation 
 
It is not yet determined if the expression of type I MAGE genes is an epiphenomenon 
occurring after global hypomethylation in chaotic cancer cells, or if MAGE genes are 
expressed to provide a survival advantage to tumor cells.  
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Expression in mice  
 
In 1995, De Backer and his team identified homologous genes of the human type I 
MAGE genes in mice (De Backer et al, 1995). Using a probe specific for the MAGEA1 
human gene, they identified three homologous genes, initially named Smage-1, -2, -3; and 
then renamed Mage-b1, -b2 and –b3.  
 
Later, twelve murine homologous genes (eight homologues to the MAGEA human 
gene and four homologues to the MAGEB human gene) were identified. These mouse genes 
present a chromosomal localisation, a structure and an expression pattern similar to the human 
genes (Forslund et Nordqvist, 2001).  
 
These findings support that the mouse model represents an attractive tool for studying 
the functions of type I MAGE genes, as their homologues exist in human.  
 
 
Expression in male germ cells 
 
  Type I MAGE genes are expressed during spermatogenesis (Figure 3).  For instance, 
MAGEA1 and MAGEA4 proteins are expressed in the cytoplasm and the nucleus of 
spermatogonia and primary spermatocytes, hinting the possible role of these proteins in the 
early steps of spermatogenesis (Takahashi et al. 1995). In mice, Mage-a genes are also 
expressed in spermatogonia (Chomez et al. 1995). On the other hand, Mage-b proteins were 
detected in spermatids, post-mitotic cells that will differentiate into spermatozoids (Clotman 
et al. 2000).  
 
 Epigenetic regulation, such as methylation, plays a crucial role in spermatogenesis. It 
has been demonstrated that de novo methylation occurs in the pro-spermatogonia. The 
methylation pattern is completed by the end of the first meiosis (Oakes et al., 2007; Carrell et 
al., 2010). Nevertheless, some genes are expressed early in spermatogenesis but are silenced 
in the maturing spermatid by gradually acquiring methylation in post-meiotic spermatocytes 
(Ariel et al., 1991, Ariel et al., 1994; Carrell et al, 2010). 
 
 In view of these observations, a possible hypothesis is that type I MAGE genes, 
whose expression is controlled by methylation, could play a role at different stages of 
spermatogenesis. 
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Figure 3: Steps of spermatogenesis. Spermatogenesis takes place in seminiferous tubules in a 
centripetal cell flow. After proliferation by mitosis, spermatogonia differentiate in primary 
spermatocytes. The first meiosis allows the generation of secondary spermatocytes and the 
second gives rise to spermatids. The last step is spermiogenesis, during which round 
spermatids become spermatozoids freed from the lumen of seminiferous tubules. 
 
 
 
2) Roles of type I  MAGE genes  
 
 Influence of the type I MAGE on the tumor suppressor p53  
 
  An interesting aspect about type I MAGE proteins is their influence on the p53 tumor 
suppressor. The p53 tumor suppressor gene, inactivated in 50% of cancers, is involved in cell 
cycle progression, apoptosis, senescence, cell migration and invasion (Ladelfa et al., 2012). 
The mode of action of the p53 tumor suppressor protein is double. First, p53 is a  transcription 
factor able to induce expression of target genes playing a role in apoptosis or in cell cycle 
control, for instance. Second, the p53 protein also acts at the mitochondrial level by increasing 
the membrane permeability and by inducing apoptosis through the activation of the caspases 
cascade. 
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 In normal unstressed conditions, the level of p53 proteins is maintained low through 
degradation by the E3 ubiquitin ligase MDM2 (Mouse Double Minute 2) (Muller et al., 
2011). Moreover, the structural state of p53 prevents its binding on target genes by masking  
its DNA binding sites. When cells are undergoing cellular stress, such as DNA dammages, 
p53 protein is stabilized by post-translational modifications in order to play its tumor 
suppressor role. Interstingly, MAGE genes are able to inhibit p53 activity by three different 
ways (as summarized in figure 4A).  
 
   First, MAGEA proteins interfere with the functions of p53 by interacting with SKIP 
(Ski interacting protein), an adapter protein essential for the expression of p21. The protein 
p21 is a target gene of p53 involved in cell cycle progression by inhibition of the Cdk (cycline 
dependent kinases) (Laduron et al., 2004). Actually, SKIP counteracts the apoptosis mediated 
by p53 via selective regulation of p21Cip1 mRNA splicing (Chen Y et al., 2011, Zhao et al, 
2006). On the other hand, MAGEA1 is able to recruit histone deacetylases (HDAC) on p53, 
leading to inhibition of the p53 transcriptional activity through deacetylation of histones 
around the DNA binding sites of p53 and deacetylation of the p53 protein itself. These 
findings could explain why MAGEA provides a survival advantage when expressed in cells 
treated with p53-dependent DNA-damaging agents, such as etoposide or doxorubicin (Monte 
et al., 2006).  
 
  Another mechanism by which MAGE proteins influence p53 involves RING-
containing E3 ubiquitin ligase, a subtype of E3 ligases. E3 ligases are major components of 
the ubiquitination cascade by binding E2 enzymes coupled to their substrate, leading to the 
degradation of the substrate in a proteasome-dependent way (Doyle et al., 2010). MAGE 
proteins interact trough their MHD with RING proteins, without implication of the RING 
domain. For example, MAGE proteins (specifically MAGEC2, MAGEA2, MAGEA3 et 
mMageb) are able to bind the TRIM-28 (Tripartite motif-containing 28) protein, also named 
KAP-1 (Krüppel Associated protein-1), a RING protein that targets p53 for its proteasomal 
degradation. Doyle and his team demonstrated that MAGE proteins bind and induce a 
stimulating conformation change of TRIM-28 leading to the degradation of p53 in a 
proteasome-dependent manner (Figure 4B) (Doyle et al., 2010; Yang et al, 2007). Moreover, 
TRIM-28 joins several other ubiquitin ligases that promote ubiquitin-mediated degradation of 
p53 including MDM2, another ubiquitine ligase which targets p53. In summary, MAGE genes 
are able to induce the proteasomal degradation of p53 by stimulating both TRIM-28 and 
MDM2 proteins.  
 
 
 Finally, MAGEA proteins inhibit the p53-dependant transcription by direct interaction 
with the DNA binding domain of the p53 core  (Marcar et al., 2010). This hypothesis was 
confirmed by an augmentation of the binding between p53 and its target genes p21, Bax and 
Puma after MAGE-A genes silencing. 
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Figure 4: (A) Influence of type I MAGE genes on the tumor suppressor p53. Type I MAGE genes 
could inhibit p53 by three different ways: (1) By recruitment of HDAC leading to the inactivation of 
p53 after deacetylation. (2) By stimulation of E3 ubiquitin ligases, among them TRIM28 that induces 
p53 ubiquitylation and proteasome degradation. (3) By interaction with the DNA binding domain of 
p53. (B) Illustration of the processus of degradation of p53 through the ubiquitylation cascade. Type I 
MAGE proteins bind and stimulate the TRIM-28 protein, a E3 ligase containing a RING domain. 
Once activated, TRIM-28 binds p53, leading to it’s degradation in a proteasome dependent manner. 
TRIM-28 can also recruit MDM2 for the degradation of p53 in the proteasome.  
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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Induction of the hypoxic response  
 
  During tumor growth, cells in the center of the tumor become so distant from blood 
vessels that their environment becomes hypoxic. The hypoxia inductible factor 1 (or HIF-1 
factor), a transcription factor induced in hypoxic conditions, is composed of two sub-unit: 
HIF-1α and HIF-1β (Porporato et al, 2011). The β sub-unit is constituvely present in the cell 
nucleus, while the α sub-unit is only stabilized in absence of oxygen. Effectively, in 
normoxia, HIF-1α is hydroxylated by the prolyl-hydroxylase PHD2 to be recognized by the 
VHL (von Hippel Lindau) protein which mediates its degradation in a proteasome-dependent 
way. In a hypoxic environment, HIF-1α, non hydroxylated by the PHD2, is not directed in the 
proteasomal pathway. The association of HIF-1α with the β sub-unit leads to the obtaining of 
a functionnal transcription factor targeting a set of genes involved in the glycolytic switch and 
angiogenesis.  
 
Interestingly, it has been demonstrated that MAGEA proteins are able to influence this 
pathway in hypoxic cancer cells. Indeed, MAGEA2, MAGEA9 and MAGEA11 proteins 
interact and  suppress the activity of the prolyl hydroxylase 2 (PHD2), which maintain HIF-α 
proteins at low levels in normoxic conditions (Aprelikova et al., 2009). This way, MAGEA 
proteins stabilize the HIF-1α subunit to enhance the hypoxic response.  
 
 
Inhibition of caspases  
 
  Another function of MAGEA genes is their involvement in the onset of apoptosis 
through inhibition of caspases. For instance, the binding of MAGEA3 protein to the pro-
caspase 12, inhibits the activation of caspase 12 involved in endoplasmic reticulum stress 
(Sang et al., 2010). Tumor cells expressing type I MAGE genes would be protected against 
such damages, conferring to them a survival advantage (Morishima et al, 2002).  
 
 
Pro-apoptotic activity  
 
  Interestingly, the N-terminal truncated form of MAGEA4 was reported to have a pro-
apoptotic activity. First, an interaction between MAGEA4 and the gankyrin, an oncoprotein 
over-expressed in hepatocarcinoma, has been reported. It has been demonstrated that 
MAGEA4 was able to decrease the oncogenic activity of the gankyrin (Nagao et al, 2003). 
Second, it has also been observed that MAGEA4 is cleaved by a caspase-dependent protease 
after DNA damages to generate the MAGEA4ΔN1 fragment. This fragment binds to Miz-1, a 
zinc finger transcription factor responsible of the inhibition of p21. Once activated, the protein 
p21 blocks the cell cycle. Moreover, MAGE-A4∆N1 decreases the Bcl-xL protein level, 
inducing cell death (Sakurai et al., 2004). 
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V. INVOLVEMENT IN TUMORIGENESIS   
 
   Some evidences support the hypothesis that type I MAGE genes could have an active 
role in cancerogenesis. First, it is demonstrated that some MAGEA proteins confer resistance 
to chemotherapeutic drugs, as paclitaxel, doxurubicin or etoposide (Duan et al, 2003; Monte 
et al., 2006; Suzuki et al., 2007). Moreover, MAGEA genes expression is associated with 
tumor invasiveness, lymph node metastasis, poor prognosis and advanced clinical stage 
(Sang, Wang et al, 2011; Jung et al., 2005). The inhibition of the p53 and HIF induction are 
also consistent with these hypothesis. These findings make the type I MAGE genes an 
attractive target for immunotherapy.  
 
1) Chemoresistance 
 
Chemotherapy is the major treatment to kill cancer cells, characterized by a high division 
speed. Chemotherapeutic drugs can be divided in different categories according to their mode 
of action:  
 
- Antimitotic agents 
The antimitotic agents are so-called because of their ability to interfere with the 
mitotic spindle. For instance, some chemotherapeutic drugs as paclitaxel or docetaxel 
are able to destabilize the mitotic spindle by inhibiting the polymerization of tubulin.  
 
- Intercalating agents 
The intercalating agents are able to incorporate the DNA, inducing the blockage of 
polymerase and of the DNA synthesis. For instance, doxurubicin is an intercalating 
agent.  
 
- Antimetabolit agents 
The antimetabolit agents work by inhibiting DNA synthesis. The 5-fluorouracil (5-FU) 
is an example of antimetabolit. 5-FU is an analog of pyrimidin used by the thymidilate 
cyclase, no more available for thymidine synthesis.  
 
- Topoisomerase inhibitor agents 
The inhibitors of topoisomerase induce the stabilization of the DNA breaks performed 
by the topoisomease. Etoposide, for example, is able to stabilize double strand breaks 
generated by topoisomease II.  
 
 
However, the efficiency of chemotherapy is entraved by the ability of some cancer 
cells to develop resistance mechanisms to cell death. Intruigingly, type I MAGE genes are 
reported to participate to cell chemoresistance. Indeed, MAGEA1 expression is correlated 
with resistance to apoptosis when melanoma cells are treated with classical chemotherapeutic 
drugs, as paclitaxel, doxurubicin or etoposide (Duan et al, 2003; Monte et al., 2006; Suzuki et 
al., 2007). Our lab previously demonstrated a chemoresistance of MCF-10A cells expressing 
MAGEA1 (Elise Srour, unpublished data). The tested drugs were etoposide, 5-fluorouracil 
and docetaxel. Etoposide and 5-fluorouracil are reported to work through a p53-dependent 
manner, but not docetaxel. This observation suggested the involvement of a p53-independent 
mechanim of chemoresistance induced by MAGEA1. 
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  Such a mechanism could involve ATP-binding cassette (ABC) transporters, major 
mediators of multidrug resistance (Ansbro et al., 2013, Gillet and Gottesman, 2012). ABC 
transporters mediate the efflux of several compounds through cells or organelles membranes. 
They act as keepers of the organism by regulating the permeability of several organic barriers, 
as the blood-brain barrier, testis, placenta, kidney, liver and gastro-intestinal tract. This way, 
ABC transporters control the excretion of toxins to protect the cells. Nineteen genetic diseases 
have been reported to be associated with mutations in these genes. ABC genes are also well 
known for their role in allowing cancer cells to evade response to treatment through efflux of 
chemotherapeutic drugs (Ansbro et al., 2013, Gillet and Gottesman, 2012). 
 
2) Cell migration and invasion 
 
  It has been demonstrated that the expression of type I MAGE genes is associated with 
advanced clinical stage in melanoma. Effectively, Barrow and his team discovered that the 
frequency of MAGEA1 expression in primary melanoma was 20% and increases up to 51% in 
distant metastasis (Barrow et al, 2006). These results were consistent with those obtained by 
Brasseur et al, who reported that MAGEA1 was expressed in 16% of primary melanomas and 
48% of metastatic melanomas (Brasseur et al, 1995). These results suggest an acquisition of 
the MAGEA1 antigen with progressive stage of cancer, as in thicker and ulcerated 
melanomas.  
 
  Another study published in 2013 showed that the forced expression of MAGEA3 
resulted in p21 down-regulation, accelerated cell cycle progression but also in cell migration 
and invasion (Liu et al, 2013). Firstly, in vitro studies, consisting in scratch tests and 
tridimensional matrigel chambers were performed. Scratch tests involve performing a wound 
in a cell monolayer in order to observe the time take by cells to invade the scratch (see 
Materials and Method for details). The matrigel chamber is another method used to study cell 
migration by reconstituting the basal membrane in vitro. Actually, the invasive cells are able 
to pass through the membrane by secretion of proteases, while the non-infiltrative cells will 
stay in the first compartment. These two in vitro assays revealed that MAGEA3 significantly 
promotes cell migration and invasion (Liu et al, 2013). Furthermore, the team also proves that 
MAGEA3 enhances thyroid tumor growth and lung metastasis in vivo by using a mouse 
model injected by MAGEA3-positive cells.  
 
These findings suggest that several MAGE proteins can be involved in migration and 
invasion of cancerous cells. It implies that MAGE antigens could be used as prognosis marker 
or targets for immunotherapy.  
 
3) Immunotherapy 
 
  In an experiment performed fifty years ago, mice with malignant tumors were treated 
by surgical excision of the tumor. When these mice were injected with cells from the excised 
tumor, they did not develop the tumor again. This experiment raised the hypothesis that tumor 
cells present specific antigens able to induce an immune response. This finding was the 
observation indicating that immunotherapy in the treatment of cancer could be effective. The 
purpose is to stimulate the immune system against tumor cells (Van Pel et al, 1992). 
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  As mentioned above, the specific expression of MAGE proteins in cancer cells makes 
them an attractive target for immunotherapy. Male germ cells do not express HLA, which 
ensures a specific immunogenic targeting of cancer cells (Sang et al., 2010).  Several methods 
are conceivable to target MAGE antigens in immunotherapy (Gillespie & Coleman 1999; 
Caballero & Chen 2009): 
 
- A first approach is the direct vaccination of the patient with MAGE peptides  
- A second method consists to vaccinate the patient with cancer cells expressing  
MAGE peptides at their surface  
- Finally, it is also possible to inject antigen-presenting cells (APC) of the patient  
cultivated in presence of MAGE peptides to stimulate T cells. 
 
MAGE peptides are currently being investigated as immunizing agents in clinical 
trials. These studies are showing encouraging results for gastro-intestinal cancers, oesophagus 
carcinomas, lung carcinomas and melanomas (Bhutani et al., 2011; Forslund et Nordqvist, 
2001). Specifically, a MAGEA3 vaccine is tested in phase 3 as adjuvant therapy for lung 
cancer and melanoma (Marchand et al., 1995;  Brichard et al., 2013).  
 
 
VI. METHODS OF TRANSGENESIS  
 
One of the goals of my project is to generate and characterize MAGEA1 transgenic 
mice. The purpose is to study the involvement in tumor development, chemoresistance and 
development of metastasis in vivo.  For this reason, I detailed in this paragraph the two 
common methods of mouse transgenesis. Table 1 compares the advantages and disadvantages 
of the two methods.  
 
  The first method is additive transgenesis. The DNA is directly injected in mouse 
blastocysts where it integrates the genome randomly. The mechanism of integration of the 
transgene into chromosome of zygotes by microinjection in the male pronucleus is not well 
characterized. Hypothesis is that the introduction of DNA could induce enzymatic activities of 
DNA repair in the genome of the embryo. Afterwards, zygotes are transferred into the 
oviducts of surrogate mothers.  
 
  The second method is the targeted transgenesis (the “knock-in” method), consisting in 
modifying a genomic sequence in a chosen integration site. Embryonic stem cells (ES cells), 
that are totipotent cells isolated from the inner cell mass of the blastocyst, are used in this 
technology. ES cells can be genetically modified in vitro by electroporation or by retroviral 
infection. The transgene is integrated in the genome of ES cells by homologous 
recombination. Selected genetically modified ES cells are injected in blastocysts, then 
implanted in a pseudo-pregnant mouse. The development of the blastocyst will give rise, in 
50% of the cases, to a chimeric mouse. The transgene can then transmit to the following 
generation to establish a lineage of transgenic mice.  
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Table 1  
 
Additive transgenesis  
 
Advantages Disadvantages 
Faster than targeted transgenesis Random integration site (coding or no 
coding sequence) 
Any DNA sequence can be injected (BAC, 
YAC, plasmid) 
Efficiency of 3 to 10%  
 High levels of technicality of the 
experimenter  
 Integration can induce deletions, 
duplication, translocation  
 Copy number of the transgene is often >1 
 
 
Targeted transgenesis  
 
Advantages Disadvantages 
In vitro  selection of ES cells (for the site of 
integration, the transgene copy number, 
karyotype) 
Slower than additive transgenesis 
Choice of the integration site  Heavy method 
No limitation of size  Positive selection marker required  
 
VIII.  OBJECTIVES AND WORKPLAN  
 
 Type I MAGE genes could play an active role in tumorigenesis, chemoresistance or 
metastasis. In this work, we explored the possible role of MAGEA1 in tumorigenesis, using a 
series of in vivo and in vitro models (Figure 5). Transgenic mice ectopically expressing 
MAGEA1 were generated in order to assess the effect of MAGEA1 expression on tumor 
incidence and agressiveness in vivo. In parallel, we investigated p53 dependent and 
independent oncogenic functions of MAGEA1 in vitro with a particular focus on cell 
chemoresistance and migration.  
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Figure 5: Objectives and workplan. In vivo studies consisted in the generation of two 
MAGEA1 transgenic mice. The first mouse, named TYRP-MAGEA1 transgenic mouse, was 
obtained by additive transgenesis. The MAGEA1 cDNA was placed under control of the 
tyrosinase promoter, which is specific for melanocytes. The second mouse, the Rosa26-
MAGEA1 transgenic mouse is an inducible mouse model that was obtained by targeted 
transgenesis. In this model, the induction of MAGEA1 expression is dependend on the 
excision of the STOP cassette located between the CAG promoter and the MAGEA1 coding 
sequence. The STOP cassette, flanked by lox sites, can be excised by crossing the Rosa26-
MAGEA1 transgenic mice with mice expressing the Cre-recombinase. The in vitro studies 
focused on chemoresistance assays performed with p53 proficient (MCF-10A and MCF-7) 
and p53 deficient (Hep3B) cells. Expression of ABC transporters was monitored in MCF-10A 
and Hep3B cells. Finally, scratch tests were performed in order to evaluate the effect of 
MAGEA1 on cell migration in MCF-10A cells and in Hep3B cells. 
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MATERIALS AND METHODS  
I. PINSULATOR-TYRP-MAGEA1  PLASMID DESIGN  
 
 The TYRP-MAGEA1 construct was linearized using BamHI and NotI restriction 
enzymes.  On the other hand, the pcDNA1-MAGEA1 plasmid was digested with the same 
enzymes to recover the MAGEA1 insert. After 1 hour of incubation at 37°C, the products of 
the two digestions were analyzed by a gel electrophoresis on 1% agarose gel in Tris-acetate 
buffer supplemented with ethidium bromide. 
 
   Wizard SV Gel and PCR Clean-UP System (PROMEGA, A9281) kit was used to 
recover DNA from the gel. To allow ligation, the vector was dephosphorylated with Shrimp 
Alkaline Phosphatase (SAP) (NEW ENGLAND BIOLABS) in a total volume of 100µl. After 
1 hour of incubation, the sample was treated with 1µl of EDTA 0,5M and heated at 70°C for 
10 minutes in order to inactivate the enzyme. The mixture was extracted with one volume of 
phenol-chlorophorm and centrifuged at 14000g for 15 minutes. DNA was then precipitated in 
2,5 volumes of ethanol 100% after adding 0,1 volume of sodium acetate (NaAc) 3M. After 
one hour of incubation at -80°C, the sample was centrifuged at 14000g for 10 minutes 
generating a pellet that was washed with 70% ethanol. After air-drying, the DNA pellet was 
diluted in distilled water.  
 
  The dephosphorylated linearized vector and the MAGEA1 insert in a 1:3 proportion 
were ligated by mixing 400000U/ml T4 DNA ligase (NEW ENGLAND BIOLABS M0202S) 
and 2µl ligase buffer. The ligation mixture was incubated overnight at 16°C. The next 
morning, 50µl of DH5-α electro-competent bacteria were mixed with 2µl of the ligation 
product. Transformed bacteria were then spread onto LB agar treated by 50mg/ml ampicilin 
in a Petri dish and grown overnight at 37°C. For screening, PCR was performed with primers 
specific for MAGEA1 gene. The PCR program used was: 5 minutes at 95°C, 30 seconds at 
95°C, 30 seconds at 57°C, 1 minute at 72°C and 5 minutes at 72°C. Second, third and fourth 
steps were performed thirty times.  
 
II. MICE GENOTYPING  
 
  Candidate transgenic mice obtained by pronucleus micro-injection were screened by 
PCR for the presence of the MAGEA1 transgene in their genome. DNA was extracted from a 
little piece of the tail. Tissue was treated with 200µl lysis buffer (containing 100 mM TrisHCl 
pH 8, 500mM KCl and 10% Tween 20). After heating 5 minutes at 95°C, 10µl of proteinase 
K (20mg/ml) was added to the samples and incubated overnight at 55°C.  
 
Proteinase K was inactivated by heating 5 minutes at 94°C. After 10 minutes of 
centrifugation at 13000g, 1 µl of the supernatant and MAGEA1-specific primers were added 
to PCR mix. The PCR program used was 5 minutes at 94°C, 30 cycles of [30 seconds at 
94°C/30 seconds at 57°C/1 minute at 72°C], a final elongation step of  5min et 72°C 
terminated the reaction.  
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III. CELL CULTURE 
 
  All cells were cultivated in a humidified incubator at 37°C and 5% CO2. Regular cell 
passage was required to avoid contact inhibition and to provide new nutriments. To this end, 
cells were washed with phosphate buffer saline (PBS) (LONZA, BE17-516F) to eliminate 
dead cells, debris and any residual medium. Trypsin-EDTA (LONZA, BE17-161
E
) was then 
added in order to detach cells from the dish. After a few minutes at 37°C, complete medium 
was added to the trypsinized cells and an appropriate number of cells were collected and 
adequately diluted on a new support. Cells were resuspended in Trypan Blue (ratio 50:50) to 
stain non viable cells and transferred to a KOVA counting chamber. Cell concentration was 
determined as follows: Cell concentration (cell number/ml) = counted cell number x 2 
(dilution factor) x 1000. 
 
 Hep3B cells  
The Human Hepatoma cell line Hep3B is derived from a human hepatocellular carcinoma. 
Hep3B cells are deficient for p53. For this reason these cells were used to study p53-
independent mechanisms. Hep3B cell line was cultivated in Dulbeco’s Modified Eagle 
Medium (DMEM 1X) (LONZA, BE12-604F) supplemented with 10% Fetal Bovine Serum 
(FBS) (LONZA, DE14-801F) and 1% penicillin/streptomycin (LONZA, DE17-602E). 
 
MCF-10A cells  
MCF-10A cell lines are mammary epithelial cell lines untransformed but spontaneously 
immortalized (Soule et al, 2010). MCF-10A cells were cultivated in DMEM/F12 (1:1) 1X 
(GIBCO, 11320-074) medium supplemented with 5% horse serum (HS) (GIBCO, 26050-
088), 1% of penicillin/streptomycin, 10µg/ml of insulin (SIGMA ALDRICH, I9278-5ML), 
100ng/ml of choleric toxin (SIGMA ALDRICH, C8052-1MG), 500ng/ml of hydrocortisone 
(SIGMA ALDRICH, H0396-100MG) and 20ng/ml of human epidermal growth factor (hEGF) 
(SIGMA ALDRICH, E9644-2MG 
 
MCF-7 cells 
MCF-7 cells, a human epithelial cell line, was the first mammary cell line cultivated for a 
long term. MCF-7 cells were cultivated in DMEM 1X, 10% FBS and 1% of 
penicillin/streptomycin and 15nM Hepes.  
 
293T cells  
293T cells, derived from Human Embryonic Kidney (HEK) were used for lentiviral 
packaging. The 293T cell line was cultivated in the same standard medium (DMEM 1X, 10% 
FBS and 1% penicillin/streptomycin), supplemented by glutamax 100X and 0,6mg/ml of 
glucose before transfection.  
 
B16 cells  
B16 melanoma cells are obtained from a mouse melanoma (C57BL/6J). This cell line is a 
suitable transfection host. The B16 cell line was cultivated in DMEM 1X, 10% FBS, 1% 
penicilin/streptomycin and glutamax 1X.  
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IV. CALCIUM-DEPENDENT TRANSFECTION AND CELL TRANSDUCTION 
 
   293T cells, derived from human embryonic kidney cells (HEK293), were used to 
produce lentiviral particles. On the first day, 293T cells were enumerated and 1,3 million cells 
were plated in a T25 flask. Before transfection, the cell medium (DMEM1X, 10%FBS, 1% 
penicillin/streptomycin) was supplemented with glutamax 1x and 0,6mg/ml of glucose. Cells 
were transfected with two different lentiviral vectors: (1) a vector expressing MAGEA1 and 
(2) an empty vector, as a negative control.  
 
One day later, once cell confluence reached 30-40%, mixtures were prepared to allow 
calcium-dependant transfection and viral particles production. These mixtures, adapted for a 
T25 flask, consisted of 500µl HBS 2X, 62,5µl CaCl 2M, 3,5µg of the lentiviral vector for the 
calcium-dependant transfection. In order to package and produce viral particles, 1,25µg 
pMDLg/PRRE, 1,25µg pRSV-Rev and 1,25µg VSVg vectors (ADDGENE), coding for gag, 
env and rev genes, were added to the mixture. Mixtures were then added to the cells.Two days 
after transfection, the supernatant containing viral particles was collected and centrifuged 5 
minutes at 12000g and filtered through a 0.45µ filter (MILLIPORE, MA01730) and frozen at 
-80°C.  
 
Cell infection was performed by addition of viral particles (1,5ml per T25 plate) and 
polybrene 5µg/ml (CHEMICON INTERNATIONAL, TR-1003-G). After eight hours of 
incubation, cell culture was diluted in standard medium. A dose curve was carried out to 
establish neomycin concentration for cells selection.  
 
V.  WESTERN-BLOT 
 
  To obtain protein extracts, the cells were first rinsed with PBS 1X and treated with 
lysis buffer 1X (0.05 M Tris pH 8, 0.15 M NaCl, 0.005 M EDTA, 1% Nonidet P40 and 0.5% 
sodium desoxycholate) with a protease inhibitor cocktail diluted 100X (Proteoblock). After 
ten minutes of incubation on ice, cell membranes were degraded, thereby freeing cytoplasmic 
and nuclear proteins. The supernatant was cleared by a centrifugation during 15 minutes at 
14000g at 4°C. Concerning mice protein lysates, the organs were first dissected, weighted 
then grinded in lysis buffer 1X (10X the volume of the weight of the organ). The samples 
were incubated twenty minutes on ice. After vortexing, samples were centrifuged 15 minutes 
at 14000g at 4°C.  
 
The Pierce BCA Protein Assay Kit (THERMO SCIENTIFIC 23225) was used to 
determine protein concentrations of the lysates by densitometry. Protein concentrations were 
determined on basis of a standard growing concentration of BSA (Bovine Serum Albumin). 
Fifteen to thirty micrograms of proteins were mixed with 5µl of Laemmli buffer 5X (0.5 SDS, 
10% glycerol, 6.25 mM Tris pH 6.8 0.003% bromophenol blue and 25 mM DTT 
(dithiothréitol)) and distilled water to reach a total volume of 25 µl. The sample was heated at 
95°C during 5 minutes to denature proteins.   
 
  Proteins were migrated onto an SDS-PAGE gel (sodium dodecyl sulphate 
polyacrylamide gel electrophoresis), composed of a stacking gel - to assemble samples before 
migration - and a migration gel, separating proteins according to their molecular weight.  
Proteins were then transferred onto PVDF (Polyvinylinedifluoride) membranes. After protein 
transfer during 1.5 hours, PVDF membranes were blocked for 30 minutes with a buffer made 
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of PBS 1X, 0.05% of Tween 20 and 5% of powdered milk. Membranes were then incubated 
in primary antibody diluted in PBS 1X, 0.05% Tween 20 and 1% milk at 4°C overnight. After 
three washes of 10 minutes in PBS 1X, Tween 20 0.05%, membranes were incubated in the 
adapted secondary antibody, conjugated with the Horseradish Peroxydase (HRP), allowing 
revelation by chemoluminescence (Polyclonal Goat Anti-Mouse Immunoglobulins/HRP 
DAKO P0447; Polyclonal Goat Anti-Rabbit Immunoglobulins/HRP DAKO P0448). After 
three additional washes, HRP substrates (Supersignal West Pico Chemiluminescent Substrate 
THERMO SCIENTIFIC 34095; Supersignal West Femto Maximum Sensitivity Substrate 
THERMO SCIENTIFIC 34080) were added to the membranes.  Proteins could then be 
revealed by autoradiography. 
 
VI. REVERSE TRANSCRIPTION AND QUANTITATIVE PCR 
 
 
  After washing with PBS 1X, cells were collected in 1ml of TRI-Reagent
TM
 for a cell 
pellet of 5 to 10.10
6 
cells. The resulted cell lysate was centrifuged at 12000g for 10 minutes at 
4°C. After treatment with chloroform (200µl chloroform per mL of TRI-Reagent
TM
) and 
vortexing, an emulsion was obtained. After an incubation of 15 minutes, an additional 
centrifugation allowed formation of three distinct phases: red organic phase (containing 
proteins), interphase (DNA) and aqueous phase (RNA). The aqueous phase was collected and 
precipitated in isopropanol (500µl per of TRI-Reagent
TM
). The pellet was washed by ethanol 
75% and diluted in 25µl of distilled water. Concentration and purity of the extracted RNA 
were measured through optic density by the Nanodrop Spectrophotometer. The extraction of 
RNA from mice was performed in a slightly different way. Organs were collected and grinded 
in 10 volumes of TRIzol. After adding 200µl of chlorophorm, the tube was shaken vigorously 
by hanging inversion. After 5 minutes of incubation at room temperature, samples were 
centrifugated 15 minutes at 4°C and at 12000g allowing the formation of three distinct phases: 
red organic phase (containing proteins), interphase (DNA) and aqueous phase (RNA). Next 
steps were performed in the same manner than with cell extracts.  
 
The SuperScriptTM II Reverse Transcriptase kit (INVITROGEN, 18064-014) was used to 
perform reverse transcription. To this end, 1µg of RNA was mixed with 1µl dNTP Mix 
10mM (INVITROGEN, 18427-013), 1µl Random Hexamer Primer (FERMENTAS, S0142) 
and 12µl DEPC water. After a five minutes heating at 65°C, 40U/µl of enzyme RNAse and 
4µl buffer First-Strand 5X were added to each sample. These samples were then treated 10 
minutes at 45°C, 30 minutes at 50°C and 5 minutes at 85°C to inactivate the enzyme. After 
diluting the cDNA in 40µl DEPC water, samples were analyzed by the Nanodrop 
Spectrophotometer to evaluate cDNA concentration.  
 
The last step was the quantitative PCR allowing us to estimate genes expression in 
different conditions, in comparison with a housekeeping gene. To this end, cDNA is mixed 
with 2,4µM primer forward, 2,4µM primer reverse and 10µl SYBR Green/ROX qPCR Master 
Mix (containing the DNA polymerase, dNTP in adequate buffer, a colouring agent SYBR 
Green and the passive colouring agent ROX) (MOLECULAR RESEARCH CENTER 
TR118). The PCR program was included 2 minutes at 50°C, 10 minutes at 95°C, 40 fold 15 
seconds at 95°C and 2 minutes at 60°C. Data analysis was performed by the 7300 System 
software. To interpret results, we calculated ∆Ct to normalized genes expression according to 
the housekeeping gene (GADPH) and the ∆∆Ct to compare our results between our control 
and tested samples. 
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VII. MTT TEST 
 
  The MTT test was used to evaluate growth and cell viability, through a measure of cell 
metabolism. MTT, or 3-(4,5-dimethylthiazol-yl)-2,5-diphenyltetrazolium bromide (SIGMA 
ALDRICH, M2128-1G), can be transformed by mitochondrial reductases in a substance 
generating purple crystals. This reaction can only be performed in active metabolic cells, 
giving an idea of cell viability. Absorbance of purple crystals was measured by a 
spectrophotometer. Cells were cultivated in a 24-wells plate (50,000 cells per well) in an 
adequate culture medium.  
 
The next day, cell medium was replaced by new medium containing chemotherapeutic 
agents as etoposide (SIGMA ALDRICH, E1383-25MG), docetaxel (SIGMA ALDRICH, 
01885-5MG-F) or 5-fluorouracil (SIGMA ALDRICH, F6627-1G). After different post-
treatment times, each well was treated with 500 µl of MTT solution (2,5mg/ml PBS) and 
incubated for two hours. Five-hundred microliters of DMSO (dimethylsulfoxyde) was added 
in each well before an additional incubation of one hour. To finish, cell absorbance was 
determined by spectrophotometry. 
 
 
VIII. SCRATCH TEST 
 
  The scratch test is a common and easy technique to study cell migration. The test starts 
with the creation of a wound in the cell monolayer. Actually, once cells reach confluence in a 
Petri dish (of sixty millimetres), the wound is performed using a tip of a p200 pipette. Cells 
migrate to close the wound and restore cell contact. After changing the medium by medium 
deprived with serum (DMEM, FBS 0,1%, PS 1%), several pictures are taken, at time zero and 
at different intervals after the scratch.  
 
This way, it is possible to study and compare the migration rate of different cells 
types.For each interval, three scratches are performed (left-medium-right segments) and for 
each of these, three points are photographed (top-medium-bottom points). Marks on the Petri 
dish allow photography of these same points in time. A software of image processing 
(PhotoFiltre 7) make de measure of the wound possible. Afterwards, the quantification of the 
scratch test was carried out by calculating the opening percentage of the scratch: 
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RESULTS:  
 IN VIVO MODELS 
 
I. ADDITIVE TRANSGENESIS: THE TYRP-MAGEA1 TRANSGENIC MICE  
 
1)  The TYRP-MAGEA1 transgene 
 
  One of the goals of our work is to study the involvement of MAGEA1 in 
tumorigenesis using in vivo models (Figure 5). For this reason, the lab started the construction 
of transgenic mice ectopically expressing MAGEA1 in melanocytes. These mice were 
obtained by additive transgenesis (Figure 6). The global strategy was to clone the MAGEA1 
coding sequence under control of the tyrosinase promoter (TYRP), specific for melanocytes. 
The TYRP-MAGEA1 cassette was flanked by insulators sequences, which should help to 
protect the transgene from the possible spreading of neighbouring heterochromatin and of the 
activity from distally located enhancers (West AG, Gaszner M and Felsenfeld G, 2002). 
 
 
The MAGEA1 cDNA was inserted into a plasmid named TYRP-plasmid, under 
control of the tyrosinase promoter. This tyrosinase promoter, specific for the melanocyte 
lineage, was used to drive MAGEA1 expression specifically in melanocytes. (Figure 6A-B-C) 
(Delmas et al, 2007). The MAGEA1 cDNA was inserted between the BamHI and NotI 
restriction sites in the TYRP-plasmid, the recombinant plasmids were analyzed by restriction 
and PCR (Figure 6D-E). The ability of this construct to drive the expression of MAGEA1 in 
melanoma cells was evaluated by western-blotting after transient transfection of B16 
melanoma cells. Results presented in Figure 6F indicate that the vector efficiently induced the 
expression of MAGEA1 in B16 cells.  
 
 
The next step was to transfer the TYRP-MAGEA1 cassette between the ClaI and NotI 
restriction sites, located in the pInsulator vector (Figure 6G-H). This way, the transgene was 
flanked by insulators sequences to obtain a protection from undesirable regulations. The 
structure of the construct pInsulator-TYRP-MAGEA1 was validated by PCR and restriction 
analysis with SalI and FseI (Figure 6I-J-K). Results show an efficient linearization of 
pInsulator-TYRP-MAGEA1 by FseI. Double digestion by FseI and SalI generated two 
fragments, one of which corresponds to the fragment of interest that will be purified and 
injected in the pronucleus of mouse zygotes.     
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Figure 6: (A) Plasmid map of pcDNA1 containing the MAGEA1 cDNA located between 
BamHI and NotI restriction sites (B) Electrophoresis gel analysis of the pcDNA1-MAGEA1 
digestion with BamHI and NotI (C) Electrophoresis gel analysis of the TYRP plasmid 
digestion: ND (non-digested) or digested by BamHI, NotI, SacII, PstI, SmaI enzymes (D) 
Plasmid map of TYRP-MAGEA1 plasmid (E) PCR screening on colonies susceptible to 
contain TYRP-MAGEA1 plasmid (F) Western-blot analysis of proteins extracted from B16 
cells transiently transfected with TYRP-MAGEA1 plasmid or empty TYRP plasmid, as 
negative control. Tubulin, a structural protein of microtubules, is used as loading control (G) 
Plasmid map of pInsulator plasmid (H) Electrophoresis gel analysis of the pInsulator plasmid 
digestion: ND or disgested by SacII enzymes (I) Plasmid map of pInsulator-TYRP-MAGEA1 
(J) PCR screening of colonies susceptible to contain the TYRP-MAGEA1 pInsulator-plasmid 
(K) Electrophoresis gel analysis of the pInsulator-TYRP-MAGEA1 plasmid digestion with 
FseI or with FseI and SalI restriction sites.  
 
 
2)  GENERATION OF TYRP-MAGEA1 TRANSGENIC MICE 
 
 
  Having obtained the derived TYRP-MAGEA1 construction, the next step was to 
generate MAGEA1 transgenic mice by additive transgenesis. Oocytes were recovered from 
mated mice and TYRP-MAGEA1 DNA was directly injected in the male pronucleus. Injected 
eggs were then implanted into the oviduct of pseudo-pregnant mice (work performed by Dr 
Younes Achouri, UCL).  
 
We obtained a total of 64 mice that were genotyped using a PCR specific for 
MAGEA1. Nine of these mice were MAGEA1 positive and used as founders of the transgenic 
lineage (Figure 7). The founders were mated with wild-type mouse (C57B6) to determine if 
the MAGEA1 transgene could be transmitted to the progeny. The percentage of transmission 
was estimated to approximately 25%.  
 
 
 
Figure 7: PCR genotyping of DNA extracted from mice tail (mice 0 to 64). Positive control 
corresponds to pcDNA3-MAGEA1 while distilled water replaces DNA for the negative 
control.  
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3)  CHARACTERISATION OF TYRP-MAGEA1 TRANSGENIC MICE  
 
  The next step after obtaining MAGEA1 transgenic mice was to characterize 
expression of MAGEA1 in each of the mice lineages. Each founder and its lineage could be 
different according to the site of integration, the transgene copy number and MAGEA1 
expression.  
 
In order to determine the expression of MAGEA1 in TYRP-MAGEA1 transgenic 
mice, western-blot analyses were performed on proteins extracted from skin of three different 
TYRP-MAGEA1 transgenic mice lineages (lineages n°1, n°2 and n ° 3) (Figure 8). The skin 
of a wild-type mouse was used as negative control (CT-). Proteins extracted from MCF-7 
MAGEA1 
were employed as a positive control (CT+). The antibody anti-MAGEA1 6C1 was 
used to detect the MAGEA1 protein. This mouse monoclonal antibody reacts broadly with 
different members of the MAGEA family (MAGEA-1, -2, -3, -4, -6, -10 and 12). The 
western-blotting, performed with a polyclonal goat anti-mouse immunoglobulin conjugated to 
HRP (horseradish peroxydase), revealed a band of approximately 50kDa. This result was 
interpreted as aspecific, given that the band was also detected in the negative control (Figure 
8A). The experiment was reiterated using the CleanBlot secondary antibody, allowing the 
detection of immunoblotted target protein bands without interference with immunoglobulin 
heavy chains (MW: 49.7 kDa). However, no MAGEA1 protein could be detected in any 
TYRP-MAGEA1 mice, except with the positive control, suggesting that the first blot detected 
the immunoglobulin heavy chains of mouse tissues (Figure 8B). A possible explanation is that 
the level of MAGEA1 transgenic protein could be insufficient to be detected by western-blot 
analysis, a situation often observed in transgenic mice.  
 
To solve this problem, quantitative PCR following reverse transcription was 
performed in order to quantify the MAGEA1 mRNA copies in four different mice of each 
lineage (Figure 9). The number of cycles (Ct) was normalized with regard to a housekeeping 
gene, the GAPDH (glyceraldehydes-3-phosphate). This way, we obtained a value of ∆Ct 
allowing us to calculate the fold change (2
-∆∆Ct
) and, by that MAGEA1 relative expression. 
Figure 9 represents the expression of MAGEA1 in the skin of four TYRP-MAGEA1 mice 
from different lineages (lineage n°1, n°2, n°3, n°4). Skin from a MAGEA1 negative mouse 
was used as negative control. Preliminary results acquired from four different mice lineages 
revealed a transcription of MAGEA1 at different levels in the skin. The relative expression 
was determined by calculating a percentage of fold change, compared to a maximum fold 
change (100%). The maximum fold change was attributed to the mouse n°1, which presents 
the highest expression of MAGEA1. The mouse of the lineage n°2 presents a number of 
transcripts of 66% compared to the mouse n°1 (100%). For mice lineages n°3 and n°4, the 
percentage of transcripts were respectively 3,8% and 1,4%. We also performed quantitative 
RT-PCR analyses on other organs: testis, heart, brain and liver. The skin of mice 1 was used 
as positive control. Organs of a wild-type mouse were employed for negative controls. No 
MAGEA1 transcript was detected either in testis, heart, brain or in liver. These results raised 
the hypothesis that MAGEA1 is expressed specifically in the skin but not in other organs of 
the transgenic mouse, just as expected. Nonetheless, further analyses on other TYRP-
MAGEA1 tissues are needed to confirm this hypothesis. 
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Figure 8: Western-blot analysis of proteins from TYRP-MAGEA1 transgenic mice after 
revelation with (A) the HRP-coupled polyclonal goat antibody and with (B) the CleanBlot 
Detection Reagent.  
 
 
 
 
 
 
 
 
Figure 9: Quantitative PCR analysis following reverse transcription. Relative expression of 
MAGEA1 in the skin of different TYRP-MAGEA1 mice coming from four different lineages 
(lineages n°1, n°2, n°3 and n°4). Skin of mouse lineage n°1 was used as reference (100%), as 
it corresponds to the highest expression of MAGEA1. Negative controls correspond to a wild-
type mouse. Error bars correspond to standard deviation for n=2.  
 
 
 
 
 
       Relative expression of MAGEA1 in the skin of TYRP-MAGEA1 mice  
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II. TARGETED TRANSGENESIS: THE ROSA26-MAGEA1 TRANSGENIC MICE   
 
  In parallel to the TYRP-MAGEA1 transgenic mice obtained by additive transgenesis, 
our lab developed MAGEA1 transgenic mice by targeted recombination. The MAGEA1 
insert was cloned in the Ai6 plasmid (Figure 10A) (Madisen et al, 2010). The vector contain 
the MAGEA1 coding region under the control of the CAG promoter, a strong promoter often 
use to induce a high transgene expression. A STOP cassette flanked by lox sites is inserted 
between the MAGEA1 coding region and the promoter, preventing the expression of 
MAGEA1. The construction was electropored in embryonic stem cells (ES cells). Genetically 
modified ES cells were injected in blastocysts and re-implanted in a surrogate mouse.  
 
 
 Twenty-six chimeric mice were obtained and genotyped by a PCR specific for 
MAGEA1 (Figure 10B). Nine chimeric mice (namely 7 males and 2 females) were found to 
be MAGEA1 positive and used as founders. These chimeric mice were mated with wild-type 
mice (C57B6) and the obtained pups were genotyped. Specific PCR to MAGEA1 revealed 
that five mice among thirteen were positive (Figure 10C). These MAGEA1 transgenic mice 
should not express MAGEA1, as its expression is prevented by the STOP cassette.  
 
 
 These Rosa26-MAGEA1 transgenic mice are currently mated with mice expressing 
the Cre recombinase. Some of the pup mice would contain both the MAGEA1 transgene and 
the Cre recombinase, which will induce the expression of MAGEA1 by excision of the STOP 
cassette. It should be possible to target specific tissues for MAGEA1 expression. Indeed, 
various transgenic mice expressing the Cre recombinase in tissues can be used, inducing a 
specific expression of MAGEA1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
(A) 
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Table 2: Genotyping of Rosa26-MAGEA1 chimeric mice 
 
                   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10: (A) Plasmid map of the ai6 plasmid, in which MAGEA1 insert was cloned. CAG 
Pr: strong and ubiquitous promoter; Stop: floxed stop cassette; Blue triangle: Frt sites 
recognized by Flp recombinase; Yellow triangle: Lox sites recognized by Cre recombinase; 
ZsGreen: fluorescent protein; WPRE: woodshuck hepatitis virus post-transcriptional 
regulatory element; AttB/AttP: PGQ-Neo-marker; Neo: resistance gene to 
neomycin/geneticin. The ai6 plasmid is flanked by homolog sequence of the chromosome 
Rosa26 to allow recombination in the genome of the mice (Figure adapted from Madisen et 
al, 2010) (B) PCR genotyping of DNA extracted from tail mice (mice 0 to 41). Positive 
control corresponds to a TYRP-MAGEA1 positive mouse while distilled water replaces DNA 
for the negative control (C) PCR genotyping of DNA extracted from tail mice (mice 0 to 13). 
Positive control corresponds in a TYRP-MAGEA1 positive mouse while distilled water 
replaces DNA for the negative control. Genotyped mice correspond to brown mice, except 
mice 3-4-5 from founder 1, which are black mice (as second negative controls).  
 
 
 
 
 
 
 
    MAGEA1 Male/Female 
Lineage n°1 1 F 
Lineage n°2 1 F 
Lineage n°3 1 M 
Lineage n°4 2 F+M 
   
 
(B) 
 
 
 
 
(C) 
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IN VITRO MODELS   
 
I. MAGEA1 AND CELL CHEMORESISTANCE  
 
1)  CHEMORESISTANCE IN A P53 WILD-TYPE CELL MODEL  
 
 
   In addition to the projects with the MAGEA1 transgenic mice, our lab also aimed to 
study the involvement of MAGEA1 in chemoresistance through in vitro cell models (Figure 
5). For this purpose, two cell models were generated: the first was a mammary epithelial cell 
line untransformed but spontaneously immortalized: the MCF-10A cell line. The second 
model was a transformed immortalized epithelial mammary cell line: MCF-7 cells. Both 
MCF-10A and MCF-7 cells were transducted by a lentiviral vector containing MAGEA1 
under control of the PGK (phosphoglycerate kinase) promoter (or empty lentiviral vector, as 
control). Cells were selected with neomycin. The MCF-10A
CT 
(control) and MCF-10A 
MAGEA1 
(expressing MAGEA1)
 
cells as well as MCF-7
CT 
and MCF-7
MAGEA1
 cells were used in 
chemoresistance assays.  
 
  The expression of MAGEA1 in transduced MCF-7 and MCF-10A cells was monitored 
by western-blotting (Figure 11). Additionally, the p53 protein level was assessed in order to 
evaluate the repression of p53 by MAGEA1 in our cell model.  In this purpose, proteins were 
collected 30 minutes or 1 hour after treatment with etoposide (or without treatment, as 
control). Indeed, the stabilization of p53 protein requires a cellular stress, as a treatment with 
a DNA damaging agent such as etoposide. Figure 11A revealed a lower level of the p53 
protein in presence of MAGEA1 1 hour after the treatment with etoposide in MCF-10A cells. 
Figure 11B shows a diminution of p53 levels in MCF-7 cells 1 hour post-treatment. These 
results are in accordance with the known role of MAGEA1 in the degradation of p53.  
 
 
 
 
  
 
 
(A)        (B) 
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Figure 11: Western-blot analysis of proteins from (A) MCF-10A and (B) MCF-7 cells 
transducted by lentiviral vectors containing or not MAGEA1 (MCF-10A 
MAGEA1
 or MCF-
10A
CT
 and MCF-7 
MAGEA1
 or MCF-7
CT
) and treated (ETO) or not (NT for no treatment) with 
etoposide. α-Tubulin was used as loading control.  
 
 
After validation of our cell models, MCF-10A and MCF-7
 
cells were used to analyze 
the effect of MAGEA1 on chemoresistance upon treatment with 3 chemotherapeutic drugs: 
docetaxel, 5 fluorouracil and etoposide. Chemotherapeutic agents concentrations inducing 
50% of MCF-10A cell death (IC50) were evaluated at 50 µM for etoposide, 15 nM for 
docetaxel and 100 µM for 5-FU. Regarding MCF-7 cells, IC50 were estimated at 60 μM for 
etoposide, 20 nM for docetaxel and 100 μM for 5-FU. MCF-10A and MCF-7 cells expressing 
or not MAGEA1 were cultivated in presence of chemotherapeutic drugs to monitor cell 
survival after treatment. Cell survival was measured through MTT tests at 0 (untreated cells), 
24, 48 and 72 hours post-treatment. The results shown in Figure 12 suggested an improved 
cell survival in presence of MAGEA1, whatever the chemotherapeutic treatment and the cell 
line. Moreover, the difference of survival percentage of MAGEA1 positive cells compared to 
control cells increases with the duration of the treatment.  
 
 
Concerning MCF-10A cells, survival of MCF-10A
CT
 and MCF-10A
MAGEA1
 became 
significantly different 24 hours after etoposide treatment and highly significant after 48 hours 
(Figure 12A). MCF-10A
MAGEA1
 resisted better than the controls to 5-FU treatment 48 hours 
after the treatment (Figure 12B). Finally, MCF-10A cells appeared to be less sensitive to 
docetaxel, showing a slower decrease in survival curves. Survival ratio differences between 
MCF-10A
CT
 and MCF-10A
MAGEA1
 were significant after 48 hours (Figure 12C).  
 
 
In parallel, Figure 12D revealed that the difference of survival percentage between 
MCF-7
MAGEA1 
and MCF-7
CT 
becomes significant 48 hours after etoposide treatment and 
highly significant after 72 hours. After 5-FU treatment, the survival percentage of MCF-7 
MAGEA1 
is significantly higher than the control during all treatment duration, with maintenance 
at 41% at 72 hours (Figure 12E). Finally, the treatment with docetaxel (Figure 12F) induces a 
higher survival rate of MCF-7
MAGEA1 
extremely significant at 48hours and significant at 72 
hours compared to control cells. To summarize, these results hinted the hypothesis that 
MAGEA1 confer a resistance to apoptosis in two different cell models after various 
chemotherapeutic treatment.  
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Figure 12: Survival curves of MCF-10A
MAGEA1 
and MCF-10A
CT 
cells after 0, 24, 48 and 72 
hours of treatment with (A) 50 μM etoposide, (B) 15 nM docetaxel and (C) 100 μM 5-
fluorouacil. Survival curves of MCF-7 
MAGEA1
 and MCF-
7CT 
after 0, 24, 48 and 72hours of 
treatment with (D) 60 μM etoposide, (E) 20 nM docetaxel and (F) 100 μM 5-fluorouacil. 
Error bars correspond to standard deviation for n=3. Student test was used to determine if 
survival percentages differences between MCF-10A 
MAGEA1
/ MCF-7
 MAGEA1
 and MCF-10A 
MAGEA1 
/ MCF-7 
CT
 were extremely significant (***), highly significant (**) significant (*) or 
non-significant (ns). 
  
 
2) CHEMORESISTANCE IN A P53 DEFICIENT CELL MODEL  
 
 Our next purpose was to determine if MAGEA1 could confer chemoresistance 
independently of p53. It is known that cell death induced by etoposide and 5-FU is dependant 
of the p53 pathway. Etoposide stabilizes double strand breaks after inhibition of the 
topoisomerase II. The maintenance of DNA breaks leads to the activation of the kinase ATM 
(ataxia telangiectasia mutated), a serine/threonine kinase. ATM binds and neutralizes 
MDM2, an ubiquitine ligase responsible for p53 degradation. In this manner, the p53 protein 
is stabilized, leading to a p53-dependent apoptosis (Heisig et al, 2009).  
 
In the same way, 5-FU is also reported to work through a p53-dependent way. 5-FU, 
an analog of pyrimidin, is incorporated in DNA then excised by a nucleotide repair complex. 
This reaction creates single strand DNA breaks, stimulating the kinase ATM and the 
apoptosis dependent of p53 (Grem et al. 2001; Cheng et al. 2012). Both etoposide and 5-FU 
thus induce p53 activation through genotoxic stress, inducing transcription of genes involved 
in cell cycle arrest and apoptosis (Meley et al., 2010; Sun et al., 2007). Consequently, 
chemoresistance conferred by MAGEA1 to etoposide and 5-FU could be due to its anti-p53 
activity.  
 
In contrast, the mode of action of docetaxel is described to be independent of p53. 
(Mhaidat NM et al., 2007 a; b). Docetaxel is an anti-mitotic agent causing the stabilization of the 
β-tubulin, the blockage of the mitotic spindle and cell apoptosis. It has been demonstrated that p53 
inhibitors do not confer chemoresistance to docetaxel, suggesting a p53-independent mechanism 
(Mhaidat et al. 2007). These observations raised a new question: Could MAGEA1 confer a p53-
independent chemoresistance? With the aim to answer this question, we set up a p53-
independent cell model by forcing expression of MAGEA1 in Hep3B cells, which are 
deficient for p53 and do not express type I MAGE genes. Western-blot assay validated that 
Hep3B cells do not express MAGEA1 or other MAGE proteins that can be recognized by the 
MAGEA1 antibody (Figure 13A). Expression of MAGEA1 in Hep3B cells was induced by 
transduction as described above (see details in Materials and Methods). Western-blot analysis 
was then performed to verify the expression of MAGEA1 in the Hep3B
MAGEA1
 cell line 
(Figure 13B).   
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Figure 13: (A) Western-blot analysis of proteins extracted from Hep3B cells and MCF-7 cells 
stably expressing MAGEA1 gene (MCF-7
MAGEA1
) or not (MCF-7
CT
) as positive or negative 
control, respectively. KU-80 was used as loading control. (B) Western-blot analysis of 
proteins extracted from Hep3B cells, previously transducted by the lentiviral vector 
containing MAGEA1 (Hep3B
MAGEA1
) or by the empty (Hep3B
CT
) vector.  
 
 
 
Chemoresistance was examined after treatment with DNA damaging agent, just as 
performed on MCF-10A and MCF-7 cells. Results shown in Figure 14A and 14B do not 
reveal any resistance of Hep3B
MAGEA1 
cells after etoposide and 5-FU treatments. Indeed, the 
differences between survival of Hep3B
MAGEA1 
and Hep3B
CT 
cells treated with etoposide or 5-
FU were not significant. These observations indicate that MAGEA1 does not confer 
chemoresistance to Hep3B
p53-/-
 cells after etoposide and 5-FU treatment. 
 
 
In contrast, Figure 14C revealed a significant difference in the survival percentage 
between Hep3B
MAGEA1 
and control cells 48 hours after docetaxel treatment. This difference 
becomes highly significant after 72 hours post-treatment with a survival percentage 
maintained at 63% in presence of MAGEA1, in comparison with 43% in control cells.  These 
results suggest that MAGEA1 is able to confer chemoresistance to Hep3B
p53-/-
 after docetaxel 
treatment, reported to work independently of the p53 pathway. In other words, MAGEA1 
could confer chemoresistance by a p53-independent mechanism.  
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Figure 14: Survival percentage of Hep3B
MAGEA1
 and Hep3B
CT
 after 0, 24, 48 and 72hours of 
treatment with (A) 50 μM etoposide, (B) 100 μM 5-fluorouacil and (C) 15 nM docetaxel. 
Error bars correspond to standard deviation for n=3. Student test was used to determine if 
survival ratio differences between MCF-10A
MAGEA1
 and MCF-10A
CT
 were, significant (*) or 
highly significant (**) or no-significant (ns).  
 
(A) 
 
 
 
 
 
 
 
 
 
 
 
(B)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 (C)  
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II. MAGEA1 AND ABC TRANSPORTERS EXPRESSION  
 
Our next goal was to identify the p53-independent pathway responsible for the 
chemoresistance conferred by MAGEA1 after docetaxel treatment (Figure 5). As they are an 
important mediators of multidrug resistance, we investigated the effect of MAGEA1 on the 
expression of ATP-Binding Cassette (ABC) genes specifically on ABC-B, -C and –G 
families, that are known to confer multi-drug resistance.  
 
1) ABC transporters expression in a p53 wild-type cell model  
 
MCF-10A
MAGEA1
 cells were used to quantify the levels of several ABCs transcripts by 
quantitative RT-PCR in a p53 wild-type cell model (Figure 15). The choice of ABCs 
transporters (namely ABC- G2, -C1, -C2, -C3, -C4 and –C5) was done according to their 
susceptibility to be expressed in the mammary epithelium and thus in MCF-10A cells. Results 
show an up-regulation of ABCs transporters in presence of MAGEA1 (Figure 15). 
Specifically, ABCG2 gene presents a strong over-expression of 23, 7% in MCF-10A
MAGEA1
 
cell compared to control cells. The ABCC1, ABCC2, ABCC4 and ABCC5 genes are less up-
regulated, with a mRNA relative expression of 4,7%, 7%, 7,5% and 8,9%, respectively. A 
possible explanation is that the up-regulation of ABC transporters could participate to the 
resistance to apoptosis of MCF10A 
MAGEA1
 after etoposide treatment.  
 
 
 
 
 
Figure 15: Quantitative PCR analysis following reverse transcription. Relative expression of 
ABCs genes in MCF-10A cells expressing MAGEA1 compared to control cells (MCF-10A
CT
) 
48 hours after etoposide treatment. The expression in control cells is considered as reference 
= 1. Error bars correspond in standard deviation for n=3. 
ABC transporters expression in  
MCF-10A
MAGEA1
 cells compared to MCF-10A
CT 
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2) ABC transporters expression in a p53-deficient cell model 
 
   In order to assess the possible role of p53 in the induction of ABCs, we repeated the 
experiment in the p53-deficient Hep3B cells. ABC-C1, -C2, -C4, -C5, -B1 and –B11 were 
selected for their specificity for the hepatic tissue. Results indicated in Figure 16 do not reveal 
any up-regulation of ABC transporters in Hep3B
MAGEA1 
compared to control cells (Hep3B
CT
). 
 
 
 
 
 
Figure 16: Quantitative PCR analysis following reverse transcription. Relative expression of 
ABCs genes in Hep3B cells expressing MAGEA1 compared to control cells 48 hours after 
etoposide treatment. The expression in control cells is considered as reference = 1. Error bars 
correspond to standard deviation for n=3. 
 
 
These results show that ABCs transporters, often involved in multi-drug resistance are 
induced by MAGEA1 in MCF-10A cells, but not in Hep3B. A possible explanation is that the 
induction of ABCs transporters could be dependent of the p53 pathway. This hypothesis is 
supported by a study published in 1997 which demonstrate that p53 was able to repress the 
transcription of ABC transporters by direct binding to their promoter regions (Thottassery et 
al., 1997). However, no conclusions can be made at this time, as the experiment was 
performed with two different cell models. To confirm this hypothesis, we need to compare 
identical cells except for the expression of p53. 
 
 
 
 
 
ABC transporters expression in  
Hep3B
MAGEA1
 cells compared to Hep3B
CT 
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III. MAGEA1 AND CELL MIGRATION 
 
 
1) EFFECT OF MAGEEA1 ON MIGRATION IN A P53 WILD-TYPE CELL MODEL  
 
  In order to explore other oncogenic properties of MAGEA1, the role of MAGEA1 in 
cell migration and invasion was assessed in the lab (Figure 5) (Elise Srour, unpublished data). 
Cell migration is a crucial step for tumor development, as it allows cancer cells to invade the 
surrounding tissues. Additionally, Jung and his team had proved an association between 
MAGEA genes and development of metastasis, but no in vitro evidences of a role for 
MAGEA1 in cell migration was described (Jung et al., 2005).  
 
 
We performed scratch tests on MCF-10A cells, expressing or not MAGEA1. The 
principle of scratch tests is to create a wound in a cell monolayer in order to measure the 
speed of cell migration. Figure 17 shows the pictures of MCF-10A
CT 
or MCF-10A
MAGEA1 
at 
different times after the scratch. The Figure 19A shows the opening percentage of the wound 
at different time after the scratch. Twelve hours after the scratch, MCF-10A
MAGEA1
 cells had 
partially closed the wound and the difference of migration between MCF-10A
 MAGEA1 
and 
control cells became significant. At 16 hours, MAGEA1 positive cells had totally closed the 
scratch, showing a difference highly significant compared to control cells. Control cells 
required twenty-four hours to completely close the wound. These results suggest an ability of 
MAGEA1 to stimulate the migration of MCF-10A cells.  
 
 
 
2) EFFECT OF MAGEA1 ON MIGRATION IN A P53-DEFICIENT CELL MODEL  
 
  Subsequently, we aimed to study the effect of MAGEA1 in the p53 deficient cell 
model (Hep3B). Scratch tests were performed on Hep3B
MAGEA1 
and Hep3B
CT
 cells, both 
deficient in p53. Figure 18 presents the pictures taken at different intervals after the wound 
while Figure 19B displays quantitative results of the assay. Whatever the interval, Hep3B 
cells show a similar pattern of migration independently of MAGEA1 expression. After 72 
hours, the scratch was nearly closed in the two cell lineages. These scratch tests do not reveal 
any effect of MAGEA1 on migration in Hep3B cells.  
 
 
  These observations suggest that MAGEA1 is able to confer a migratory advantage to 
MCF-10A cells, but not to Hep3B, deficient for p53. It would be interesting to perform this 
experimentation of MCF-10A cells knock-out for p53 to confirm the role of p53 in this 
process. This hypothesis is in accordance with the well-known role of the p53 pathway in cell 
migration (Roger et al, 2006). Beside its involvement in cell cycle progression and apoptosis, 
p53 is also involved in the migratory characteristics of tumor cells.  
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Figure 17: Pictures of the scratch test of MCF-10A cells expressing or not MAGE-A1 (MCF-
10A 
CT
 and MCF-10A 
MAGEA1
). Pictures were taken 0h, 12h, 16h and 24h after the scratch. 
For each interval, scratch tests were performed three times at three different positions. The 
average distance between the two cell walls was measured using the software PhotoFiltre 7. 
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Figure 18: Pictures of the scratch test of Hep3B cells expressing or not MAGE-A1 (Hep3B 
CT
 
and Hep3B 
MAGEA1
). Pictures were taken 0h, 24h, 48h and 72h after the scratch. For each 
interval, scratch tests were performed three times at three different positions. The average 
distance between the two cell walls was measured using the software PhotoFiltre 7.  
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Figure 19: Quantification of scratch tests by measuring the opening percentage of the scratch 
(A) on MCF-10A
MAGEA1 
and MCF-10A
CT 
and (B) on Hep3B
MAGEA1 
and Hep3B
CT
. Errors bars 
represent standard deviation for n=3 for (A) and n=2 for (B). Student test was used to 
determine if survival percentages differences between MCF-10A 
MAGEA1
/ Hep3B
 MAGEA1
 and 
MCF-10A 
MAGEA1 
/ Hep3B 
CT
 were extremely significant (***), highly significant (**) 
significant (*) or no-significant (ns). 
 
 
 
(A)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(B) 
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DISCUSSION  
IN VIVO MODELS 
 
 
One objective of my project was to generate and start to characterize transgenic mice 
ectopically expressing MAGEA1 in melanocytes. The expression of MAGEA1 was quantified 
in four different mice lineages and different organs (skin, liver, heart, brain and testis). Brain 
and testis were chosen because of their general high susceptibility to express transgenes. 
Quantitative RT-PCR analysis revealed a transcription of MAGEA1 in the skin of each mouse 
lineage. This observation is in accordance with the expected results. Indeed, the specificity of 
MAGEA1 transcripts in the skin was predictable, as a promoter derived from the tyrosinase 
gene was used to drive the expression of MAGEA1.  Note that the tyrosinase is an enzyme 
needed for melanin production and specifically expressed in melanocytes. Melanocytes are 
also present in non-cutaneous tissues, such as in the retina of the eye, gastro-intestinal and 
genito-urinary mucosa and brain, specifically in meninges (Chudnovsky et al, 2005).  
However, MAGEA1 transcripts were undetectable in the brain of the transgenic mice. For this 
reason, analyses of other organs (containing non-cutaneous melanocytes for example) are 
required.  
 
 
The difference of MAGEA1 expression level among the different lineages could be 
explained by the transgene copy number. Indeed, additive transgenesis is known to generate 
mice with multiple transgene copies inserted in the genome in a single or multiple loci. In 
addition, the locus of insertion could also affect the expression of the transgene. The 
advantage of this phenomenon is the possibility to compare the effect of MAGEA1 according 
to its level of expression in different mouse lineages.Another objective of the work was to 
confirm the expression of MAGEA1 at a protein level in transgenic mice, through western-
blotting using the 6C1 anti-MAGE antibody. The analysis revealed a band of approximately 
45kDa but was interpreted as aspecific, given that the band was also detected in the negative 
control. The CleanBlot secondary antibody allowed the elimination of the interference with 
the immunoglobulin heavy chains. The blot did not reveal any band, except in the positive 
control, suggesting that the protein previously detected corresponded to the immunoglobulins 
present in mouse tissues. Actually, this result could be expected since the 6C1 MAGEA 
antibody is a murine monoclonal antibody with a mouse constant domain. No MAGEA1 
protein was identified in the skin of the transgenic mice. One possible explanation is that the 
level of MAGEA1 expression is too low to be detected by western-blot analysis. MAGEA1 is 
supposed to be exclusively expressed in melanocytes, which only constitute a very small 
proportion of epidermal cells. The isolation of skin melanocytes could be performed by FACS 
sorting, for instance by crossing the TYRP-MAGEA1 transgenic mice with TYRP-GFP mice.  
Another method is to analyze MAGEA1 expression by immunohistochemistry using a rabbit 
MAGEA1 antibody. This experiment is ongoing. The lab also generated MAGEA1 transgenic 
mice by targeted transgenesis, in parallel to the transgenic mice obtained by direct 
transgenesis. The inducible mouse model Rosa26-MAGEA1 presents an important advantage. 
Indeed, these mice could be crossed with different Cre expressing mice (ubiquitous, inducible 
or specifically in a certain tissue) to force the expression of MAGEA1 in different tissues to 
evaluate tumor development. 
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The long term goal of this in vivo project is to determine if MAGEA1 enhances tumor 
development, chemoresistance or metastasis. In TYRP-MAGEA1 mice, the specific 
development of melanomas will be monitored. The choice of melanocytes was motivated by 
the fact that MAGEA1 is predominantly expressed in melanoma. Moreover, skin tumors are 
easily detected by observation of the mice. We aim to induce tumor development in these 
mice using different ways:  
 
  One way consist in treating the mice with DMBA/TPA (7,12 dimethyl 
benz(a)anthracene / 12-O-tetradecanoylphorbol-13-acetate) (Indra et al, 2007). DMBA is a 
powerful carcinogen able to initiate melanoma. Just a single topical application induces the 
initiation stage. Following that, tumor growth can be provoked by TPA, a tumor promoter 
which enhances a continuous hyperplasia and inflammation, which will lead to melanomas 
(Indra et al, 2007; Yuspa et al, 1998). But the main obstacle of this experimentation is the 
experimenter biosafety.  
 
Another possible method to induce melanomas is to mate the MAGEA1 transgenic 
mice with mice spontaneously developing melanomas. The transgenic mice Ink4a
-/-
/Arf
-/-
/Ras
+/+ 
is reported to be an appropriate model for melanoma development (Figure 20).  
 
The INK4A (or p16
INK4A
) and ARF (or p14
ARF
) are tumor suppressor proteins encoded 
by the CDKN2A locus, present on the 9p21 chromosome. An alternative promoter allows the 
specific splicing of CDKN2A in two spliced isoforms: INK4A and ARF. INK4A and ARF, 
present a different first exon (1α and 1β, respectively) and common second and 
third exons but in alternating reading frames (Chin et al, 2003; Chudnovsky et al 2005). 
INKA4, a member of the INK4 (inhibitor of cyclin-dependent kinase 4) family, is able to bind 
and inhibit the cyclin-dependent kinases Cdk4 and Cdk6. The kinases Cdk4 and Cdk6 
inactivate the retinoblastoma protein (Rb) by phosphorylation, allowing the advancement of 
the cell cycle to the S phase (Serrano et al, 1993; Serrano et al, 1996). This way, INK4A loss 
leads to Rb inactivation and uncontrolled cell cycle. In other part, ARF permit the 
stabilization of the p53 tumor suppressor by inhibition of MDM2, responsible for the 
degradation of p53 in a proteasome-dependent manner. In consequence, the loss of ARF 
induces the degradation of p53 (Zhang et al, 2003). Interestingly, 25% to 40% of the familial 
melanomas present a mutation in INK4A/ARF (Aitken et al, 1999, Tsao et al, 2000). 
Furthermore, mice knock-out for the INK4A gene have a higher susceptibility to develop 
melanomas (Krimpenfort et al, 2001). All together, these observations suggest that the 
pathway INK4A/ARF is a prominent suppressor axis in human melanoma. Moreover, Chin 
and his team detect a synergism between the activation of the Ras pathway and the combined 
loss of INK4A/ARF in melanoma development in mice. Transgenic mice expressing Ras in 
melanocytes develop melanomas in 43% of the cases in 6 months-period in an INK4A/ARF 
deficient background (Ackermann et al, 2005; Chin et al, 1997; Chin et al, 2003; Huijbers et 
al, 2006).  
 
Our purpose is to mate the Ink4a
-/-
/Arf
-/-
/Ras
+/+ 
mice with the MAGEA1 transgenic 
mice in order to obtain a MAGEA1 transgenic mice which spontaneously develop melanomas 
(Figure 20). Besides, we shall monitor the size, the number and the aggressiveness of tumors 
in MAGEA1 mice compared to control mice (Ink4a
-/-
/Arf
-/-
/Ras
+/+
). It will also be interesting 
to study the state of the p53 protein in these mice by western-blot analysis after treatment with 
a DNA damaging agents. Indeed, a DNA damaging agent, as a chemotherapeutic treatment, is 
needed to stabilize the p53 protein level. Moreover, chemoresistance of the tumors in these 
mice could be evaluated.  
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Figure 20: The Ink4a
-/-
/Arf
-/-
/Ras
+/+ 
inducible mouse model of melanoma. (A) Map of the transgene 
Tyr-Ras-P1A. The tyrosinase promoter is followed by a Cre-recombinase inducible with tamoxifen (or 
OHT for 4-OH-tamoxifen) and flanked by lox sites. The H-Ras gene expression is driven by the 
tyrosinase promoter to allow a specific expression of Ras in melanocytes.  P1A corresponds to a 
surface antigen and contain the signal of poly-adenylation. The Ras transgene is introduced in mice 
with a homozygous conditional Ink4a/Arf locus, flanked by loxP sites (see (B)). (C) Map of the 
TYRP-MAGEA1 mouse and of the Rosa26-MAGEA1 mouse. Our purpose is to cross these mice with 
the Ink4a
-/-
/Arf
-/-
/Ras
+/+ 
mouse model. After OHT administration, the Cre-recombinase will recombine 
genes flanked by loxP sites, thereby inducing (D) the activation of H-Ras and P1A combined with the 
self-deletion of Cre, (E) the loss of Ink4a/Arf and (F) the expression of MAGEA1 in the inducible 
Rosa26-MAGEA1 mouse (Figure adapted from Huijbers et al, 2006).  
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An important aspect to take into account in these in vivo models is the use of the 
human MAGEA1 sequence to generate the MAGEA1 transgenic mice. There is no evidence 
that the functions of the MAGEA1 human protein are conserved in a mouse content. For this 
reason, we shall induce MAGEA1 in mouse cells and determine if MAGEA1 interferes with 
expression and functions of p53. For instance, we could evaluate the p53 transactivation 
functions by performing a luciferase reporter assay and analyzing the expression of its target 
genes p21, Bax and Puma by western-blot analysis.  
 
IN VITRO MODELS 
 
The second main goal of this project aimed to study the involvement of MAGEA1 in 
chemoresistance and migration using in vitro models. We demonstrated that MAGEA1 
conferred chemoresistance to MCF-10A and MCF-7 cells after treatment with 3 
chemotherapeutic drugs: etoposide, 5-FU and docetaxel, chosen for their distinctive mode of 
action. The chemoresistance assays were reiterated on Hep3B
MAGEA1 
and Hep3B
CT
 cells after 
treatment with the same chemotherapeutic drugs. The obtained results show a 
chemoresistance of Hep3B cells only after docetaxel treatment. Intriguingly, Etoposide and 5-
FU are reported to be dependent of the p53 pathway, by stimulating the kinase ATM. On the 
other hand, the mode of action of docetaxel is not entirely determined. Docetaxel is an anti-
mitotic able to engender the stabilization of the β-tubulin leading to the blocking of the 
mitotic spindle and cell apoptosis. Mhaidat et al hypothesized that docetaxel treatment could 
induce activation of caspase-2 (Mhaidat et al, 2007). Once activated, caspase-2 induces the 
translocation of Bax through the mitochondrial membrane, leading to mitochondrial 
apoptosis. It has been demonstrated that p53 inhibitors do not confer chemoresistance to 
docetaxel, suggesting a p53-independent mechanism (Mhaidat et al. 2007). These findings 
hint the possibility that MAGEA1 could confer chemoresistance after inhibition of caspase-2. 
Interestingly, it has been reported that MAGE proteins are able to bind and stimulate caspases 
(specifically caspase 3, 9 and 11), suggesting a possible interaction between MAGE proteins 
and caspases. For this reason, it could be very interesting to study the interference between 
MAGEA1 and caspase 2. It could be interesting to monitor the expression of caspase-2 by 
western-blot analysis in cells expressing or not MAGEA1 after docetaxel treatment.  
 
Analysis by quantitative RT-PCR revealed an over-expression of several ABC 
transporters in MCF-10A cells after treatment with etoposide. The same experiment on 
Hep3B cells, deficient for p53, revealed no significant ABCs over-expression in 
Hep3B
MAGEA1 
compared to control cells. In order to quantify the expression of ABC in 
another p53 wild-type cell model, the study of ABC transporters expression in MCF-7
MAGEA1 
and MCF-7
CT 
cells is ongoing. It can also be interesting to study the ABCs expression in these 
cell models after treatment with 5-FU and docetaxel. In addition, it would be interesting to 
evaluate the activity of ABC transporters. ABCs activity can be measured by FACS analysis 
using a fluorescent substrate of ABCs. For instance, etoposide is naturally fluorescent and 
transported by ABC-G2, hoescht is a substrate for ABC-B1, -C1 and –G2 and finally the 
rhodamine is also reported to be recognized and transported by ABC-B1. Thereafter, activity 
of ABC transporters is evaluated by FACS analysis. The measure of fluorescence will allow 
us to determine if the ABC protein had transported the substrate into the cell. Specific 
inhibitors of ABC can also be used, as the fibroblast growth factor (FGF), that target ABC-B1 
and induce its inhibition. This will permit to determine if chemoresistance is due to the 
induction of ABC transporters or not. So, we could perform chemoresistance assays with or 
without the inhibition of ABC transporters and compare the results.  
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Another purpose of my work was to study the role of MAGEA1 in cell migration. 
Scratch tests on MCF-10A cells expressing or not MAGEA1 were previously performed in 
the lab. Results revealed a faster migration of cells in presence of MAGEA1. To study the 
pathway involved in the acceleration of cell migration, we started the experiment again on 
Hep3B cells, deficient in p53, but detected no difference in cell migration. It should be 
interesting to make this experiment on MCF-10A cells knock-out for p53 to determine if the 
migration enhanced by MAGEA1 is dependent on the p53 pathway. A possible pathway 
involved in the acceleration of cell migration by MAGEA1 could implicate the E-cadherin 
protein, needed for the stabilization of the adherent junctions.  Indeed, it has been previously 
demonstrated in our lab that the level of E-cadherin, a protein essential for maintenance of 
adherent junctions, was diminished in presence of MAGEA1 (Elise Srour, unpublished data). 
Some studies showed that the inhibition of the E-cadherin is an important contributing factor 
for cell migration in cancer cells (van Roy & Berx 2008).  
 
An interesting assay to perform in these in vitro studies involve the generation of the 
same cell model for studying the p53 dependent and independent effects of MAGEA1. 
Indeed, the chemoresistance and migration assays should be repeated on MCF-10A cells 
which do not express p53, for example by using p53 targetted shRNA.  If the inhibition of p53 
restores the chemoresistance and migratory phenotype observed in Hep3B cells, we shall 
determine the p53-independent functions of MAGEA1. 
   
The soft-agar assay is the gold standard test to assess cell transformation in vitro. 
Indeed, cell transformation is characterized by several phenotypic changes such as the ability 
to grow in an anchorage independent way. Previously in the lab, soft agar test on MEFs 
(Mouse Embryonic Fibroblast) were performed (Elise Srour, unpublished data). The MEFs 
were stably transducted with the following coding sequences:  
 
- Ras 
- Myc 
- Ras + Myc 
- MAGEA1 + Myc 
- MAGEA1 + Ras  
- MAGEA1  
 
  It is important to recall that, in mice, the simultaneous expression of the oncogenes 
Ras and Myc induces cell transformation (so corresponding to the positive control). The 
MEFs expressing Ras+A1 or Myc+A1 were used to determine if MAGEA1 could enhance 
cell transformation. No colony formations were detected in these conditions. This suggests 
that MAGEA1 cannot induce cell transformation. However, expression of MAGEA1 could 
favor transformation, when combined with Ras + Myc. For this reason, it would be interesting 
to repeat this experiment with MEFs 
RAS + MYC + A1 
to compare the number or the size of colony 
with the transformed MEFs 
RAS+MYC
. Another test is to compare tumor development in mice 
injected by MEFs 
RAS + MYC + A1 
or MEFs 
RAS+MYC
.  
 
  To summarize, the in vivo part of this project consisted to the generation of a 
MAGEA1 mouse model in order to determine the role of MAGEA1 in tumorigenesis; while 
the in vitro section raised the hypothesis that MAGEA1 could confer survival and migratory 
advantages to several cell models.  
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ABREVIATIONS  
5-FU  5-fluorouracile 
   ABC ATP-binding cassette 
   APC  Antigen-Presenting Cell 
   ARF Alternate open Reading Frame  
  ATM  Ataxia Telangiectasia Mutated 
  BAC Bacterial Artificial Chromosome 
  Bax  Bcl-2-Associated X protein 
  Bcl-2 B-Cell Lymphoma 2 
   Bcl-xL  B-Cell Lymphoma-extra large 
  BSA Bovine Serum Albumin 
   CDK Cycline Dependent Kinase 
  CDKN2A Cyclin Dependent Kinase Inhibitor 2A 
  cDNA Complementary DeoxyriboNucleic Acid  
 CT Control  
    CTA  Cancer Testis Antigen 
   DMBA Dimethylbenz(a)anthracene 
  DMEM Dulbeco’s Modified Eagle Medium 
  DMSO DiMethylSulfOxyde 
   DNA DeoxyriboNucleic Acid  
   DNMT DNA methytransferase  
   EDTA Ethylenediaminetetraacetic acid 
  FACS  Fluorescent-Activated Cell Sorting  
  FBS Fetal Bovine Serum 
   FGF Fibroblast Growth Factor 
  GAGE G Antigen  
    GAPDH GlycerAldehydes-3-Phosphate 
  HBS Hepes Buffered Saline 
   HDAC Histone Deacetylase 
   hEGF Human Epithelial Growth Factor  
  HIF-1 Hypoxia Inductible Factor 1 
  HLA  Human Leucocyte Antigens  
  HRP HorseRadish Peroxydase  
  HS Horse Serum 
   IC50 Half Maximal Inhibitory Concentration 
 INK4 Inhibitor of Cyclin-Dependent Kinase 4 
 KAP-1 Krüppel Associated protein-1 
  KU-80 Lupus Ku Autoantigen Protein p80 
  MAGE Melanoma Antigen 
   MDM2 Mouse Double Minute 2 
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MHC  Major Histocompatibility Complex 
  MHD  Mage Homology Domain  
  Miz-1 Myc-interacting zinc finger protein 1 
  MTT 3-(4,5-dimethylthiazol-yl)-2,5-diphenyltetrazolium bromide  
NT No Treatment  
   PAGE Polyacrylamide Gel Electrophoresis 
  PBS Phosphate Buffer Saline  
   PCR Polymerase Chain Reaction 
  PGK PhosphoGlycerate Kinase 
  PHD2 Prolyl-Hydroxylase 2 
   PS Penicilin/Streptomycin 
   Puma  p53 Upregulated Modulator of Apoptosis 
 PVDF PolyVinylineDiFluoride 
   Ras Rat Sarcoma oncogene 
   Rb Retinoblastoma 
   RING  Really Interesting New Gene 
  RNA RiboNucleic Acid  
   SAP Shrimp Alkaline Phosphatase 
  SDS  Sodium Dodecyl Sulfate  
   SKIP Ski interacting protein 
   TET TET methylcytosine dioxygenase 1 
  TPA 12-O-tetradecanoylphorbol-13acetate  
  TRIM28 Tripartite motif-containing 28 
  TyrP Tyrosinase Promoter 
   UV  UltraViolet  
    VHL Von Hippel Lindau  
   WT          
XAGE 
Wild-type  
X Chromosome Antigen 
   YAC  Yeast Artificial Chromosome 
  
       
 
 
